INSIGHTS+

EMA Marketing Authorization of New Drugs in December 2025

Shots: Innovation in drug development continues to reshape patient care across dermatology, cardiology, immunology, oncology, respiratory medicine, and infectious diseases, as regulatory momentum in Europe remains strong toward the end of 2025. Recent EMA actions highlight how advanced biologics, precision small molecules, and next-generation vaccines are translating clinical breakthroughs into real-world impact. In December 2025, the EMA…

January 20, 2026

J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2025 (Part 02)

Shots: Novartis led biopharma dealmaking in 2025, executing 23 transactions worth $37.92B with a disciplined, high-impact strategy that balanced scale, science, and strategic fit Dealmaking was spread across high-conviction areas; neuroscience, cardiovascular disease, immunology, and RNA platforms, combining transformational acquisitions with flexible licensing partnerships to build a future-ready pipeline Standout transactions (Avidity, Monte…

January 16, 2026

The US FDA New Drug Approvals in December 2025

Shots: Innovation peaked in December 2025, as the FDA delivered a wave of approvals spanning cardiometabolic disease, infectious disease, respiratory immunology, rare hematologic disorders, and acute cardiovascular and neurologic conditions highlighting both scientific breadth and clinical precision Seven notable therapies crossed the regulatory finish line, including LIB Therapeutics’ Lerochol for LDL lowering, Innoviva’s Nuzolvence for gonorrhea, GSK’s Exdensur for asthma with eosinophilic phenotype, Cytokinetics’ Myqorzo…

January 13, 2026

PharmaShots Q4 2025 Highlights

Shots: As 2025 wrapped up, the final quarter made one thing clear: biopharma is doubling down on scale, science, and speed. From October to December, the industry saw a surge in high-value M&A and strategic collaborations, with companies racing to strengthen pipelines across neuroscience, oncology, metabolic diseases, and next-generation platforms The quarter was led by…

January 12, 2026

J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2025 (Part 01)

Shots: Lilly leads with precision and purpose with 45 deals totaling $21.22B in 2025, focusing on platform-driven, science-led partnerships across oncology, gene therapy, RNA editing, and AI-enabled discovery while building durable innovation engines rather than chasing short-term wins Strategic dealmaking over sheer volume is evident in partnerships like precision oncology with Scorpion Therapeutics and CNS delivery with Sangamo, structured to…

January 8, 2026

Key Biosimilars Events of December 2025

Shots: Regulatory and launch momentum accelerated globally in late 2025, with multiple FDA approvals, CHMP positive opinions, and EU/US launches for biosimilars referencing blockbuster biologics such as Prolia/Xgeva, Lucentis, Eylea, Xolair, Stelara, Simponi, Neulasta, Humira, Opdivo, and Keytruda—broadening patient access across oncology, immunology, ophthalmology, bone health, and allergy indications Leading biosimilar developers including Samsung Bioepis, Celltrion, Alvotech, Formycon,…

January 6, 2026

2025 Drug Approvals Outlook: A Year of Precision Across Therapeutic Frontiers

Shots: Precision, convenience, and disease modification define 2025 drug approvals as regulators reward biologically clear, patient-specific therapies that fragment legacy markets, elevate rare diseases, and prioritize meaningful outcomes over broad labels. Innovation is shifting from complexity to usability with oral, subcutaneous, topical, and on-demand therapies improving access and adherence across neurology, cardiology, endocrinology, ophthalmology, and…

January 6, 2026

The 2025 Playbook: Industry Trends Shaping the Future of Biopharma

Shots: 2025 marked a decisive inflection point for the global life sciences and biopharma industry. After several years defined by experimentation, abundant capital, and expansive innovation narratives, the industry entered a phase of disciplined execution. Strategies were stress-tested, science was closely scrutinized, and only programs with clear biological rationale and operational readiness advanced. Rather than…

December 31, 2025

Know Your Investor: ARCH Venture Partners (December’25 Edition)

Shots: ARCH Venture Partners is a leading US-based venture capital firm recognized for backing bold science and building category-defining companies across biotechnology, life sciences, and transformational healthcare, with a strong focus on company creation In 2024, ARCH completed 31 investments from Seed to Series A–F and beyond, including late-stage and private rounds. The firm backed innovators such…